1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

ReportsnReports.com: Evolution in the Pain Therapy Drugs Market : Nociceptive and Neuropathic Drug

Espicom Limited’s new report “Evolution in the Pain Therapy Drugs Market : Nociceptive and Neuropathic Drug Development” is now available at ReportsnReports.com.

PRLog - Jan. 6, 2012 - Pain Therapy Drugs Market :
As the market evolves over the next decade current market leaders will lose patent expiry and become subject to generic competition. What’s in the pipeline and which companies and products will prosper?

Pain affects around 1.5 billion people worldwide. In most cases, pain is temporary and easily treated with commonly available analgesics. For some people, however, pain is a debilitating, chronic condition. In Europe, an estimated 20% of the population suffers from chronic pain. As the population ages, the number of people with chronic pain is increasing, particularly from conditions such as osteoarthritis. Chronic pain is also associated with cancer. An estimated 30% of all cancer patients are in pain with the proportion more than doubling among people with late-stage cancer. In recent years, drug development in pain therapy has been focused mainly on reformulations of existing therapies and alternative modes of drug delivery in order to improve the safety and efficacy of existing drug groups.

Request a Sample for or Inquire before buying the report @

Drugs of the future
This report identifies 75 agents in clinical development for pain indications, of which 26 are in development for neuropathic pain. Among these, six are specifically targeting postherpetic neuralgia. Other indications specified, include: diabetic peripheral neuropathy, central neuropathic pain due to spinal cord injury or multiple sclerosis (MS), neuropathic pain in cancer, lumbosacral radiculopathy, and painful neuropathies affecting AIDS patients. Nociceptive pain indications being targeted by developers,
include: osteoarthritis pain and chronic low back pain.

This report answers key questions on:
•   What is the current clinical understanding of pain?
•   What is the status of, and commercial prospects for, currently available pain therapies?
•   What drugs are in the pipeline and what is their status?
•   Which companies are set to win, and which to lose, as the pain sector develops over the next 5 years?

About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports

7557 Rambler road,
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

# # #

ReportsnReports houses a comprehensive online library of more than 50,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites.

--- End ---

Click to Share

Contact Email:
***@marketsandmarkets.com Email Verified
Location:United States
Industry:drug market
Tags:pain therapy, drug market, drug development, pharmaceuticals, Pharma Market, pharma research report
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
Click to Share